Third quarter | January-September |
|
|
CEO Comment
"The positive research results presented during the quarter contribute to us trusting our financial goals for 2026.. Sales in our own markets
Significant events during the quarter
- In August, the
Medical University of Innsbruck,Austria , presented the findings from an in vitro study that explored the effect of ColdZyme on human cells infected with the influenza virus. The study shows that ColdZyme disrupts the infection cycle and restricts the spread of the virus to more cells. When ColdZyme was applied to infected cells, the viral load decreased by 99% compared with cells treated solely with saline solution. The researchers believe that ColdZyme would have a similar effect on other respiratory viruses. -
In September, the
University of Kent (United Kingdom ) presented the initial findings from an ongoing in vivo study where athletes use ColdZyme or a placebo for symptoms of upper respiratory tract infections. The results show that ColdZyme statistically significantly reduces the quantity of rhinovirus, the most common cause of the common cold. Moreover, individuals who used ColdZyme demonstrated statistically significantly fewer sore throat symptoms compared with individuals who used a placebo. The study, which is designed as a prospective, placebo-controlled, double-blind, and randomized trial, will be completed in the first half of 2024.
Significant events after the quarter
- No significant events have been reported after the quarter.
Other events during and after the quarter
- An abstract regarding the ongoing study at the
University of Kent has been accepted for presentation at the 7thInternational Olympic Committee Conference on the Prevention Injury and Illness in Sport. The abstract will be also published in theBritish Journal of Sports Medicine . -
The company is engaged in discussions with its partners regarding the launch in
China andJapan . In the light of the recent research findings, optimal product claims and classifications are being evaluated. -
The expansion of production capacity at the facility in
Reykjavik has continued during the year and the facility is now ready to handle an extensive increase in capacity. -
Lower than expected sales outside of
Enzymatica's own markets (Sweden ,UK ,Iceland ) has prompted discussions with the current business partners to explore constructive ways forward.
The full report is available on: www.enzymatica.com/investors/financial-reports
This information is information that
For more information, please contact:
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com
Phone: +46 708 55 11 85 | Email: stefan.olsson@enzymatica.com
For more information, please visit www.enzymatica.se.
https://news.cision.com/enzymatica-ab/r/interim-report-q3-2023-research-results-that-reshape-the-competitive-landscape,c3870569
https://mb.cision.com/Main/18091/3870569/2411671.pdf
https://mb.cision.com/Public/18091/3870569/a46529bc35211bda.pdf
(c) 2023 Cision. All rights reserved., source